Genpharm

Genpharm is a significant player in the MENA region, specializing in Rare Disease market access. Since its establishment in 2012, the company has been dedicated to providing efficient and sustainable market entry solutions for Rare Disease and specialty pharmaceutical companies aiming to expand into the Middle East and North Africa. With a strong emphasis on evidence-based medicine and ethical standards, Genpharm operates from its bases in Dubai Science Park, U.A.E., and Boston, as well as an office in Ireland. The company's expertise lies in Gene Therapy, making it a unique regional entity. It leverages a team of highly qualified MSLs and KAMs, offering regulatory, medical, PV, and logistical support. Additionally, Genpharm capitalizes on its extensive local business knowledge and a vast network of trusted partners to create market opportunities for innovative healthcare products and services. Its current partners include Novartis Gene Therapy, Orchard Therapeutics, Sarepta, PTC, Ultragenyx, Amicus, Argenx, LEO Pharma, Albireo, and Quoin. For further insights into Genpharm's business model and the Middle East pharmaceutical market, interested parties can visit www.genpharmservices.com.